ALDX

Aldeyra Therapeutics, Inc.
CAPPED RATING

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

Aldeyra Therapeutics, Inc. (ALDX) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Momentum (D-). The rating has held at C for 4 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.2 / 5.0
C
Value
B+
Factor Score 3.7 / 5.0
Growth
C-
Factor Score 2.0 / 5.0
Profitability
C-
Factor Score 2.0 / 5.0
Momentum
D-
Factor Score 0.9 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -2.6
EV / EBITDA 0.0
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -56.8%
Price Return 12M -86.7%
Catalyst Signal 0.00
Market Cap $40.4M
TTM Revenue N/A
Price / Sales N/A
ROE -45.3%

Historical Factor Score Progression

Held C for 4 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 B+ (3.7) C- (2.0) C- (2.0) D- (0.9) C+ (2.6) C (2.2)
2026-11-10 B+ (3.8) C (2.2) C- (2.0) D- (0.9) C+ (2.6) C (2.3)
2026-11-03 B+ (3.7) C- (2.1) C- (2.0) D- (1.1) C+ (2.7) C (2.3)
2026-10-27 B+ (3.7) C- (2.1) C- (2.0) D- (1.1) C+ (2.6) C (2.3)
2026-10-20 B+ (3.7) C- (2.1) C- (2.0) D- (1.0) C+ (2.6) C (2.3)
Page 1 of 4